Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | CETP | P11597 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821071 | 1.00 | CES2 (0.46) | CES2CES1CETPMEN1KMT2A | |
| SCHEMBL13207931 | 1.00 | CES2 (0.46) | CES2CES1CETPMEN1KMT2A | |
| SCHEMBL13207997 | 1.00 | CES2 (0.46) | CES2CES1CETPMEN1KMT2A | |
| SCHEMBL1818377 | 1.00 | CES2 (0.46) | CES2CES1CETPMEN1KMT2A | |
| SCHEMBL13207933 | 1.00 | CES2 (0.46) | CES2CES1CETPMEN1KMT2A | |
| SCHEMBL13997525 | 0.99 | CES2 (0.45) | CES2CES1CETPMEN1KMT2A | |
| SCHEMBL13997512 | 0.99 | CES2 (0.45) | CES2CES1CETPMEN1KMT2A | |
| SCHEMBL13997511 | 0.92 | MEN1 (0.45) | CES2CES1CETPMEN1KMT2A | |
| SCHEMBL13997524 | 0.88 | CETP (0.45) | CES2CES1CETPMEN1KMT2A | |
| SCHEMBL13997515 | 0.88 | CETP (0.45) | CES2CES1CETPMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197625-A1 | SYNTHETIC LIPOPHILIC INOSITOL GLYCANS FOR TREATMENT OF CANCER AND GLUCOSE-METABOLISM DISORDERS | TRUSTEES OF TUFTS COLLEGE | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197625-A1 | SYNTHETIC LIPOPHILIC INOSITOL GLYCANS FOR TREATMENT OF CANCER AND GLUCOSE-METABOLISM DISORDERS | UGCG, GPR119, GPI | CES2 1147/4885CES1 322/4885CETP 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.